Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: an ancillary study to the Epitopes-HPV02 trial.
Fiche publication
Date publication
novembre 2018
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr KIM Stephano
Tous les auteurs :
Bernard-Tessier A, Jeannot E, David G, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bieche I, Pierga JY, Buecher B, Meurisse A, François E, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S
Lien Pubmed
Résumé
Human papillomavirus (HPV) is found in 90% of squamous cell carcinomas of the anal canal (SCCA). We investigated the clinical validity of HPV circulating tumor DNA (ctDNA) detection in patients enrolled in the Epitopes-HPV02 trial which demonstrated the efficacy of docetaxel, cisplatin and 5FU as first-line chemotherapy (CT) in advanced SCCA.
Référence
Clin. Cancer Res.. 2018 Nov 30;: